Surgery Partners (NASDAQ:SGRY - Get Free Report) is set to post its quarterly earnings results before the market opens on Tuesday, November 12th. Analysts expect Surgery Partners to post earnings of $0.21 per share for the quarter. Individual that wish to listen to the company's earnings conference call can do so using this link.
Surgery Partners (NASDAQ:SGRY - Get Free Report) last announced its earnings results on Tuesday, August 6th. The company reported $0.21 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.20 by $0.01. Surgery Partners had a negative net margin of 1.17% and a positive return on equity of 2.96%. The firm had revenue of $762.10 million for the quarter, compared to analyst estimates of $735.94 million. During the same quarter last year, the business earned $0.25 earnings per share. Surgery Partners's revenue was up 14.2% compared to the same quarter last year. On average, analysts expect Surgery Partners to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.
Shares of SGRY stock opened at $29.22 on Tuesday. The company has a debt-to-equity ratio of 0.96, a current ratio of 1.83 and a quick ratio of 1.69. The company's fifty day simple moving average is $31.20 and its 200-day simple moving average is $28.26. Surgery Partners has a 52 week low of $22.25 and a 52 week high of $36.92.
Several equities research analysts recently commented on the stock. Citigroup reduced their price target on shares of Surgery Partners from $38.00 to $36.00 and set a "buy" rating for the company in a research report on Wednesday, August 7th. StockNews.com lowered Surgery Partners from a "hold" rating to a "sell" rating in a research note on Wednesday, August 7th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $43.00 price objective on shares of Surgery Partners in a research report on Friday, October 4th. Royal Bank of Canada restated an "outperform" rating and issued a $49.00 price objective on shares of Surgery Partners in a report on Wednesday, August 7th. Finally, Macquarie restated an "outperform" rating and set a $35.00 target price on shares of Surgery Partners in a report on Monday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Surgery Partners has a consensus rating of "Moderate Buy" and a consensus price target of $40.13.
View Our Latest Analysis on Surgery Partners
Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Surgery Partners, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Surgery Partners wasn't on the list.
While Surgery Partners currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.